VigiPallia : Résultats

SYMPTOME RESPIRATOIRE

0 sélectionnée(s) / 79 réponse(s)

(1) 2 3 4 > »

Managing severe chronic breathlessness in chronic obstructive pulmonary disease is challenging for general practitioners:

POLITIS, John ; EASTMAN, Peter ; LE, Brian ; FURLER, John ; IRVING, Louis ; SMALLWOOD, Natasha
American journal of hospice and palliative medicine, 17/09/2020, Pagination inconnue

Document en ligne

Episodic breathlessness with and without background dyspnea in advanced cancer patients admitted to an acute supportive care unit

MERCADANTE, Sebastiano ; ADILE, Claudio ; FERRERA, Patrizia ; BONANNO, Giuseppe ; RESTIVO, Vincenzo ; CASUCCIO, Alessandra
Cancers, 29/07/2020, vol.12, n°8, p. 1-10

Document en ligne

Manuel de soins palliatifs - clinique, psychologie, éthique

LE BERRE, Rozenn
Dunod , 08/2020 , 1260 p.

Outcomes of airway stents in the palliative care of patients with cancer

CATARATA, Maria Joana Pereira ; SALEIRO, Sandra ; ARAUJO, Vânia Sá
American journal of hospice and palliative medicine, 26/05/2020, Pagination inconnue

Document en ligne

Patients’ and caregivers’ experiences of driving with chronic breathlessness before and after regular low-dose sustained-release morphine - a qualitative study

FERREIRA, Diana H ; BOLAND, Jason W ; KOCHOVSKA, Slavica ; HONSON, Aaron ; PHILLIPS, Jane L ; CURROW, David C
PALLIATIVE MEDICINE, 10/06/2020, Pagination inconnue

Document en ligne

Mindful breathing for suffering

TUNG, Yu Zhen ; TAN, Seng Beng
BMJ supportive and palliative care, 24/06/2020, Pagination inconnue

Document en ligne

Palliative drug treatments for breathlessness in cystic fibrosis

JAISWAL, Nishant ; SINGH, Meenu ; AGARWAL, Amit ; CHAUHAN, Anil ; JAISWAL, Nikita
The Cochrane database of systematic reviews, 28/04/2020, vol.4, Pagination inconnue

Document en ligne

Thème : Médicaments - Pharmacie.

THERAPEUTIQUE MEDICAMENTEUSE ; MUCOVISCIDOSE ; SYMPTOME RESPIRATOIRE ; REVUE SYSTEMATIQUE

BACKGROUND: Cystic fibrosis is a life-limiting autosomal recessive genetic illness. A feeling of shortness of breath is common in cystic fibrosis, especially as the disease progresses. Reversing the underlying cause is the priority when treating breathlessness (dyspnoea), but when it is not feasible, palliation (easing) becomes the primary goal to improve an individual's quality of life. A range of drugs administered by various routes have been used, but no definite guidelines are available. A systematic review is needed to evaluate such treatments.
OBJECTIVES: To assess the efficacy and safety of drugs used to ease breathlessness in people with cystic fibrosis.
SEARCH METHODS: We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. Date of last search: 18 November 2019. We searched databases (clinicaltrials.gov, the ISRCTN registry, the Clinical Trials Registry India and WHO ICTRP) for ongoing trials. These searches were last run on 06 March 2020.
SELECTION CRITERIA: We planned to include randomised and quasi-randomised controlled trials in people with cystic fibrosis (diagnosed by a positive sweat chloride test or genetic testing) who have breathlessness. We considered studies comparing any drugs used for easing breathlessness to another drug administered by any route (inhaled (nebulised), intravenous, oral, subcutaneous, transmucosal (including buccal, sublingual and intra-nasal) and transdermal).
DATA COLLECTION AND ANALYSIS: The authors assessed the search results according to the pre-defined inclusion criteria.
MAIN RESULTS: The new searches in 2020 yielded two ongoing studies that were not relevant to the review question. Previous searches had found only one study (cross-over in design), which did not fulfil the inclusion criteria as no data were available from the first treatment period alone.
AUTHORS' CONCLUSIONS: Due to the lack of available evidence, this review cannot provide any information for clinical practice. The authors call for specific research in this area after taking into account relevant ethical considerations. The research should focus on the efficacy and safety of the drugs with efficacy being measured in terms of improvement in quality of life, dyspnoea scores and hospital stay.

Origine : PubMed

Management of respiratory symptoms in those with serious illness

PAN, Cynthia X. ; PALATHRA, Brigit C. ; LEO-TO, Wing Fun
The Medical Clinics of North America, 05/2020, vol.104, n°3, p. 455-470

Document en ligne

End-of-life care in the emergency department for the patient imminently dying of a highly transmissible acute respiratory infection (such as Covid-19)

HENDIN, Ariel ; LA RIVIERE, Christian G. ; WILLISCROFT, David M. ; O'CONNOR, Erin ; HUGHES, Jennifer ; FISCHER, Lisa M.
CJEM, 26/03/2020, p. 1-4

Document en ligne

Palliative care and the management of common distressing symptoms in advanced cancer - pain, breathlessness, nausea and vomiting, and fatigue

HENSON, Lesley A. ; MADDOCKS, Matthew ; EVANS, Catherine ; DAVIDSON, Martin ; HICKS, Stephanie ; HIGGINSON, Irene J.
Journal of clinical oncology, 05/02/2020, p. 1-11

Document en ligne

Struggling with the last breath - breathlessness at the end of life on the AMU

LANDER, M. ; MARTIN, J.
Acute medicine, 2019, vol.18, n°2, p. 105-111

Airflow relieves chronic breathlessness in people with advanced disease - an exploratory systematic review and meta-analyses

SWAN, Flavia ; NEWEY, Alison ; BLAND, Martin ; ALLGAR, Victoria ; BOOTH, Sara ; BAUSEWEIN, Claudia ; YORKE, Janelle ; JOHNSON, Miriam
PALLIATIVE MEDICINE, 06/2019, vol.33, n°6, p. 618-633

Document en ligne

Breathlessness in palliative care - a practical guide

GILLON, Suzie ; CLIFTON, Ian J.
British journal of hospital medicine, 02/02/2019, vol.80, n°2, p. 72-77

Document en ligne

Predicting outcomes following holistic breathlessness services - a pooled analysis of individual patient data

BRIGHTON, Lisa Jane ; GAO, Wei ; FARQUHAR, Morag ; BOOTH, Sara ; BAJWAH, Sabrina ; MAN, William D.-C. ; REILLY, Charles C. ; YI, Deokhee ; HIGGINSON, Irene J. ; MADDOCKS, Matthew
PALLIATIVE MEDICINE, 04/2019, vol.33, n°4, p. 462-466

Document en ligne

Assessing the exertion required to induce breathlessness in a population with advanced cancer - matching measures to the level of physical function

WHITE, Kahren M. ; AGAR, Meera R. ; CURROW, David
BMC palliative care, 10/01/2019, vol.18, n°1, p. 1-6

Document en ligne

Clinical use of an order protocol for distress in pediatric palliative care

MARQUIS, Marc-Antoine ; DAOUST, Lysanne ; VILLENEUVE, Edith ; DUCRUET, Thierry ; HUMBERT, Nago ; GAUVIN, France
Healthcare, 02/01/2019, vol.7, n°1, p. 1-11

Document en ligne

What constitutes good health care for patients with breathlessness? - perspectives of patients, caregivers, and health care professionals

SCHUNK, Michaela ; SCHULZE, Friederike ; BAUSEWEIN, Claudia
JOURNAL OF PALLIATIVE MEDICINE, 06/2019, vol.22, n°6, p. 656-662

Document en ligne

The lived experience of breathlessness for people diagnosed with heart failure - a qualitative synthesis of the literature

WALTHALL, Helen ; FLOEGEL, Theresa
Current opinion in supportive and palliative care, 30/11/2018, Pagination inconnue

Document en ligne

Management of breathlessness in palliative care - inhalers and dyspnea-a literature review

SENDEROVICH, Helen ; YENDAMURI, Akash
Rambam maimonides medical journal, 16/10/2018, p. 1-7

Document en ligne

Thème : Médicaments - Pharmacie. Cote : eD04.01.02.01

SYMPTOME RESPIRATOIRE ; DEMARCHE PALLIATIVE ; CONTROLE SYMPTOME ; DYSPNEE

INTRODUCTION: Dyspnea is prominently observed in palliative care (PC). Dyspnea can be multifactorial, primarily caused by obstructive or restrictive lung diseases or secondarily induced by various comorbidities. Numerous interventions exist, with route of administration and efficacy requiring further discussion. Despite opioids being the first line of treatment, their adverse effects lead to reluctance on the side of patients to take them, creating limitations in patient management planning.
OBJECTIVES: This paper reviews and highlights the role of inhalers for dyspnea management in PC.
METHODS: The CINAHL, CENTRAL, and OVID databases were searched for scholarly articles on the role of inhalers in dyspnea management from 1998 to the present. A grey literature Internet search was also performed via Google, the World Health Organization, and CareSearch. Twenty-five articles relevant to the subject at hand were located and summarized. The Cochrane Systematic Reviews of Health Promotion and Public Health Interventions Handbook was consulted for structuring.
RESULT: Isolated bronchodilators can be effective in dyspnea management. However, combination with opioids leads to a 52% reduction of dyspnea, demonstrating efficacy of their combined use. There is a role for conventional inhalers not only in patients afflicted with chronic obstructive pulmonary disease, but also in those where obstruction is reversible, and in cases of dyspnea not yet diagnosed.
CONCLUSION: Inhalers can be utilized as adjuvant therapy to opioids, to limit opioid use, augment responses to dyspnea, and/or minimize opioid side effects, especially in opioid-naïve patients. Correct administration can increase the efficacy of short-acting beta-agonists, long-acting beta-agonists, short- and long-acting anticholinergic agents, and inhaled corticosteroids, achieving reduction and alleviation of dyspnea.

Origine : PubMed

Control and context are central for people with advanced illness experiencing breathlessness - a systematic review and thematic-synthesis

LOVELL, N. ; ETKIND, S. N. ; BAJWAH, S. ; MADDOCKS, M. ; HIGGINSON, I. J.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 03/10/2018, p. 1-40

Document en ligne

(1) 2 3 4 > »

Actions

##titre_notice##